Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shamir R Mehta

Showing results (161-170 of 212) with videos related to

Pageof 22
Sort By:
International Journal of Cardiology|October 21, 2022
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registryJeremie Abtan, Deepak L Bhatt, Yedid Elbez, et al.
Journal of the American College of Cardiology|November 6, 2025
Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized TrialShamir R Mehta, Natalia Pinilla-Echeverri, Denise Tiong, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2025
Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trialDenise Tiong, Natalia Pinilla-Echeverri, David A Wood, et al.
European Heart Journal Open|June 12, 2025
Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trialGareth J Williams, Daniel J Taylor, Abdulaziz Al Baraikan, et al.
American Heart Journal|September 24, 2016
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudySteven Sra, Mary K Tan, Shamir R Mehta, et al.
Circulation|August 6, 2017
Subclinical Atrial Fibrillation in Older PatientsJeff S Healey, Marco Alings, Andrew Ha, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|March 31, 2025
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolismDavide Capodanno, John H Alexander, M Cecilia Bahit, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
Pageof 22

Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
International Journal of Cardiology|October 21, 2022
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registryJeremie Abtan, Deepak L Bhatt, Yedid Elbez, et al.
Journal of the American College of Cardiology|November 6, 2025
Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized TrialShamir R Mehta, Natalia Pinilla-Echeverri, Denise Tiong, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2025
Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trialDenise Tiong, Natalia Pinilla-Echeverri, David A Wood, et al.
European Heart Journal Open|June 12, 2025
Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trialGareth J Williams, Daniel J Taylor, Abdulaziz Al Baraikan, et al.
American Heart Journal|September 24, 2016
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudySteven Sra, Mary K Tan, Shamir R Mehta, et al.
Circulation|August 6, 2017
Subclinical Atrial Fibrillation in Older PatientsJeff S Healey, Marco Alings, Andrew Ha, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|March 31, 2025
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolismDavide Capodanno, John H Alexander, M Cecilia Bahit, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
Pageof 22